Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 8/20 | 0.45 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.45 |
| ▸ | ITPR1 | Q14643 | 3/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.39 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8582671 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL5523617 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL30240916 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL23563168 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL8581971 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL23563167 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL9300366 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL14437195 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL14268493 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL7529773 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| WO-2024233945-A1 | COMBINATION THERAPY OF POLIO VIRUS RECEPTOR INHIBITORS AND FUCOSE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| WO-2024077106-A2 | LEVERAGING L-FUCOSE-MEDIATED SIGNALING TO INDUCE MONOCYTE-DERIVED DENDRITIC CELL POLARIZATION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-04-11 | — | — | WO | claimed |
| US-5371203-A | Reacting a triester of L-fucose with trichloroacetonitrile to form corresponding trichloroacetimidate, followed by phosphating,hydrogenolysis, deprotecting, salt formation; a substrate for fucosyltransferases; tumor diagnosis | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1994-12-06 | — | — | US | claimed |
| EP-0502298-A2 | Process for the stereo-selective preparation of beta-fucopyranosyl phosphates and very pure GDP-fucose | MERCK PATENT GmbH (DE) | 1992-09-09 | — | — | EP | claimed |
| JP-4312598-A | — | — | None | — | — | JP | disclosed |
| EP-4731778-A2 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | Inbiose N.V. (BE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4702138-A1 | PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL | Inbiose N.V. (BE) | 2026-03-04 | — | — | EP | disclosed |
| US-20260015665-A1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML SCREENING LLC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4662305-A1 | PRODUCTION OF A DISACCHARIDE AND/OR MILK OLIGOSACCHARIDE BY A CELL WITH REDUCED SYNTHESIS OF UDP-GLCNAC | Inbiose N.V. (BE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4662224-A1 | PRODUCTION OF A SACCHARIDE BY A CELL WITH REDUCED SYNTHESIS OF LACTOBIONIC ACID | Inbiose N.V. (BE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4651963-A1 | PURIFICATION OF AN OLIGOSACCHARIDE OR OLIGOSACCHARIDE MIXTURE | Inbiose N.V. (BE) | 2025-11-26 | — | — | EP | disclosed |
| US-5371203-A | Reacting a triester of L-fucose with trichloroacetonitrile to form corresponding trichloroacetimidate, followed by phosphating,hydrogenolysis, deprotecting, salt formation; a substrate for fucosyltransferases; tumor diagnosis | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1994-12-06 | — | — | US | disclosed |
| EP-0576592-A1 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-05 | — | — | EP | disclosed |
| WO-1993024505-A1 | REDUCING INFLAMMATION BY TIME DEPENDENT ADMINISTRATION OF OLIGOSACCHARIDES GLYCOSIDES RELATED TO BLOOD GROUP DETERMINANTS | ALBERTA RESEARCH COUNCIL (CA) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993008205-A1 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-04-29 | — | — | WO | disclosed |
| JP-H04312598-A | STEREOSELECTIVE PREPARATION OF BETA-FUCOPYRANOSYL PHOSPHATE AND EXTREMELY HIGH-PURITY GDP-FUCOSE | MERCK PATENT GMBH | 1992-11-04 | — | — | JP | disclosed |
| WO-1992016640-A1 | OLIGOSACCHARIDE ENZYME SUBSTRATES AND INHIBITORS: METHODS AND COMPOSITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0502298-A2 | Process for the stereo-selective preparation of beta-fucopyranosyl phosphates and very pure GDP-fucose | MERCK PATENT GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
| EP-0502298-A2 | Process for the stereo-selective preparation of beta-fucopyranosyl phosphates and very pure GDP-fucose | MERCK PATENT GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015665-A1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | CD59, MASP2, CD58 | ITPR3 3450/4885ITPR2 3748/4885ITPR1 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.